Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation (EPIC-AIR)
| Registry | NCT07500948, acronym EPIC-AIR |
|---|---|
| Status | Not yet recruiting |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: double, prevention |
| Enrollment | 80 (Estimated) |
| Sponsor | University of Leicester (Other) |
| Conditions | Cardiovascular Disease, Asthma, COPD, Interstitial Lung Disease Due to Systemic Disease, Heart Failure, Coronary Heart Disease (CHD) |
| Interventions | Progressive Walking Exercise Programme, Real-time air quality information and guidance (Other, behavioral) |
| Dates | start 2026-10-01 (estimated), primary completion 2027-03-31 (estimated), completion 2027-08-01 (estimated), first posted 2026-03-30, last updated 2026-10-05 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
All trials for Cardiovascular Disease All trials for Asthma All trials of Progressive Walking Exercise Programme All trials of Real-time air quality information and guidance
The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an online platform that delivers both exercise prescription and air pollution guidance. Specific objectives are: (1) to determine whether access to real-time air quality data reduces modelled ambient pollution exposure (PM2.5, PM10 and NO2) during outdoor physical activity in CR/PR patients and healthy volunteers; (2) to assess the feasibility of the trial design, including recruitment, randomisation, retention, adherence and completeness of outcome data; (3) to measure the impact of the intervention on physical activity levels, health-related quality of life and cardiovascular biomarkers; and (4) to inform the design and sample size of a future definitive randomised controlled trial
EPIC-AIR is a single-site, stratified, blinded, two-arm randomised controlled feasibility trial conducted at University Hospitals of Leicester NHS Trust. Up to 80 participants comprising cardiac rehabilitation patients, pulmonary rehabilitation patients and healthy volunteers will be recruited. Following a 1-week baseline monitoring period, participants will be stratified by participant group (cardiac rehabilitation, pulmonary rehabilitation or healthy volunteer) and randomised 1:1 within strata using a computer-generated allocation sequence via the Sealed Envelope secure web-based system.
All participants will receive a Fitbit Charge 6 and a 12-week progressive walking programme delivered through the P-STEP platform. Participants allocated to the intervention arm will additionally receive real-time local PM2.5, PM10 and NO2 information and adaptive guidance concerning the timing, location, route or intensity of outdoor activity. Participants in the control arm will use the same platform and receive the same exercise guidance but without air-quality information or pollution-related guidance.
The primary outcomes are three co-primary pollutant-specific measures: weekly time-weighted mean modelled ambient PM2.5, PM10 and NO2 concentrations during moderate-to-vigorous physical activity (MVPA). Time-stamped GPS locations recorded during activity will be linked to wearable-derived activity data and contemporaneous modelled air-quality concentrations. These outcomes represent modelled ambient concentrations encountered during recorded activity rather than directly measured personal inhaled dose.
Weekly pollution exposure during the 12-week intervention will be analysed using repeated-measures mixed-effects models accounting for participant clustering, baseline exposure, study week, randomisation stratum, sex and calendar week. The principal treatment contrast will be the adjusted average intervention-control difference across the 12-week post-allocation period. Multiplicity across the three co-primary pollutants will be controlled using the Holm procedure.
The registered secondary outcome is weekly physical activity derived from wrist-worn accelerometry. Additional clinical, physiological and patient-reported outcomes will be explored. Feasibility outcomes include recruitment, retention, adherence, completeness of outcome data and adverse events. A final follow-up assessment will take place 3 months after completion of the 12-week intervention. No participants had been recruited at the time the registry record was revised.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Air Quality Information Provided | Experimental | Other: Progressive Walking Exercise Programme; Behavioral: Real-time air quality information and guidance | Participants receive the 12-week progressive walking programme through the P-STEP platform together with real-time PM2.5, PM10 and NO2 information and adaptive pollution-related guidance concerning exercise route, timing and/or intensity. |
| Air Quality Information Not Provided | Active comparator | Other: Progressive Walking Exercise Programme | Participants receive the same 12-week progressive walking programme through the P-STEP platform, with the same exercise guidance and tracking functions, but without air-quality information or pollution-related guidance. |
Sex: All, ages: 18 Years to any, accepts healthy volunteers
Inclusion Criteria: * Cohort A: Patients with long-term conditions Inclusion criteria for Cohort A are: male or female adults aged ≥18 years; clinical diagnosis of one or more of asthma, COPD, interstitial lung disease (ILD), coronary heart disease (CHD), or heart failure (HF), and signed off for exercise rehabilitation by a clinician; ownership of a GPS-enabled smartphone with internet access; ability to walk outdoors for a minimum of 5 minutes without feeling uneasy or unsteady; availability to complete the 1-week baseline period, 12-week intervention and 3-month post-intervention follow-up within the planned study period; willingness and ability to give informed consent; and willingness to wear a Fitbit device for >70% of the study duration. * Inclusion criteria for Cohort B are identical to Cohort A, with the exception that participants must have no diagnosis of asthma, COPD, ILD, CHD, or HF. Exclusion Criteria: * Exclusion criteria for both cohorts are: diagnosis of dementia, learning disability, severe mental health disorders (excluding depression or anxiety), or epilepsy; receiving palliative care; insufficient English language ability to understand study documentation and use the platform; having been advised not to exercise by a healthcare professional within the past 12 months; currently pregnant; presence of chest pain at rest; and marked unsteadiness when standing or walking.
| Facility | City | Country | Status |
|---|---|---|---|
| Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road | Leicester, Leicestershire | United Kingdom |